CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban

CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban

DA Sychev,1 OA Baturina,2 KB Mirzaev,1 E Rytkin,1 DV Ivashchenko,1 DA Andreev,2 KA Ryzhikova,1 EA Grishina,1 PO Bochkov,1 RV Shevchenko1 1Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russian Federation, Moscow, Russian Federation; 2Sechenov University, Mosc...

Full description

Bibliographic Details
Main Authors: Sychev DA, Baturina OA, Mirzaev KB, Rytkin E, Ivashchenko DV, Andreev DA, Ryzhikova KA, Grishina EA, Bochkov PO, Shevchenko RV
Format: Article
Language:English
Published: Dove Medical Press 2020-01-01
Series:Pharmacogenomics and Personalized Medicine
Subjects:
clopidogrel
polymorphism
atrial fibrillation
acute coronary syndrome
Online Access:https://www.dovepress.com/cyp2c1917-may-increase-the-risk-of-death-among-patients-with-an-acute--peer-reviewed-article-PGPM

Internet

https://www.dovepress.com/cyp2c1917-may-increase-the-risk-of-death-among-patients-with-an-acute--peer-reviewed-article-PGPM

Similar Items